Belvedere Trading’s Eli Lilly LLY Stock Holding History

Belvedere Trading’s Portfolio LLY Stock Details LLY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-300	Closed	-$322K	–	895
2025 Q4	$322K	Hold	300	–	–	﹤0.01%	364
2025 Q3	$229K	Buy	+300	New	+$223K	﹤0.01%	451
2025 Q2	–	Sell	-7,000	Closed	-$5.78M	–	928
2025 Q1	$5.78M	Sell	7,000 -100	-1%	-$83.2K	0.01%	49
2024 Q4	$5.48M	Buy	+7,100	New	+$5.88M	0.01%	59

Other funds holding LLY

Lilly Endowment Indiananapolis, Indiana $108B AUM 53.87% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

PNC Financial Services Group Pittsburgh, Pennsylvania $173B AUM 20.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Belvedere Trading's LLY Position: Q1 2025 in Review

Belvedere Trading sold out of Eli Lilly (LLY) in Q1 2025, closing a stake of 9 shares — an estimated $7.49K sold.

Belvedere Trading first reported a position in LLY in Q4 2014 and held it in 2 quarters. The position peaked at $1.52M in Q4 2014. 3,919 funds tracked by Wall St. Rank hold LLY as of Q1 2025.

Belvedere Trading reported no remaining Eli Lilly position as of Q1 2025 after selling out during the quarter.
Belvedere Trading sold 9 Eli Lilly shares in Q1 2025, an estimated $7.49K.
Belvedere Trading first reported a position in Eli Lilly in Q4 2014 and held it in 2 quarters.
Belvedere Trading's Eli Lilly position peaked at $1.52M in Q4 2014.
3,919 funds tracked by Wall St. Rank held Eli Lilly as of Q1 2025.

Based on Belvedere Trading's 13F filing for Q1 2025, filed 9 May 2025.